New hope for small cell lung cancer: immunotherapy after surgery

NCT ID NCT07149363

Recruiting now Disease control Sponsor: Alliance Foundation Trials, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. About 65 adults who had their cancer completely removed will receive the combination for 12 weeks, then durvalumab alone for another 36 weeks. The study compares their outcomes to historical data from patients who only got chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (Imfinzi) plus chemotherapy (cisplatin or carboplatin and etoposide)
What this could lead to: If successful, this could offer a new standard treatment after surgery for limited-stage small cell lung cancer, potentially delaying or preventing cancer return.
What could go wrong: This is a small, early-phase trial (65 people) comparing results to past data, not a direct control group. Immunotherapy can cause immune-related side effects, and the benefit over chemo alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER ( SCLC )

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
University of Illinois Chicago
RECRUITING

Chicago, Illinois, 60612, United States
University of Virginia Comprehensive Cancer Center
RECRUITING

Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.